{"result": "(\"entity\"<|>AMOR FERNÁNDEZ<|>PERSON<|>Amor Fernández is an author of the Manual de Endocrinología y Nutrición, which discusses treatments for dyslipidemia.)\n##\n(\"entity\"<|>VINAGRE TORRES<|>PERSON<|>Vinagre Torres is an author of the Manual de Endocrinología y Nutrición, which discusses treatments for dyslipidemia.)\n##\n(\"entity\"<|>PEREA CASTILLA<|>PERSON<|>Perea Castilla is an author of the Manual de Endocrinología y Nutrición, which discusses treatments for dyslipidemia.)\n##\n(\"entity\"<|>SOCIEDAD ESPAÑOLA DE ENDOCRINOLOGÍA Y NUTRICIÓN<|>ORGANIZATION<|>The Sociedad Española de Endocrinología y Nutrición is an organization that published the Manual de Endocrinología y Nutrición.)\n##\n(\"entity\"<|>MADRID<|>GEO<|>Madrid is the capital of Spain and the location where the Manual de Endocrinología y Nutrición was published.)\n##\n(\"entity\"<|>ESTATINAS<|>EVENT<|>Statins are widely used drugs for treating dyslipidemia and have significant evidence of benefits in cardiovascular morbidity and mortality.)\n##\n(\"entity\"<|>HMG-COA REDUCTASA<|>EVENT<|>HMG-CoA reductase is an enzyme that statins inhibit to reduce cholesterol biosynthesis in the liver.)\n##\n(\"entity\"<|>DISLIPIDEMIA<|>EVENT<|>Dyslipidemia refers to abnormal lipid levels in the blood, which statins are used to treat.)\n##\n(\"relationship\"<|>AMOR FERNÁNDEZ<|>SOCIEDAD ESPAÑOLA DE ENDOCRINOLOGÍA Y NUTRICIÓN<|>Amor Fernández is an author associated with the Sociedad Española de Endocrinología y Nutrición, which published the manual<|>7)\n##\n(\"relationship\"<|>VINAGRE TORRES<|>SOCIEDAD ESPAÑOLA DE ENDOCRINOLOGÍA Y NUTRICIÓN<|>Vinagre Torres is an author associated with the Sociedad Española de Endocrinología y Nutrición, which published the manual<|>7)\n##\n(\"relationship\"<|>PEREA CASTILLA<|>SOCIEDAD ESPAÑOLA DE ENDOCRINOLOGÍA Y NUTRICIÓN<|>Perea Castilla is an author associated with the Sociedad Española de Endocrinología y Nutrición, which published the manual<|>7)\n##\n(\"relationship\"<|>ESTATINAS<|>DISLIPIDEMIA<|>Statins are used to treat dyslipidemia, making them directly related<|>9)\n##\n(\"relationship\"<|>HMG-COA REDUCTASA<|>ESTATINAS<|>Statins inhibit HMG-CoA reductase to lower cholesterol levels, establishing a direct relationship<|>9)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: el proliferador de peroxisomas (PPAR-α), regulando varios pasos del metabolismo lipídico. En los estudios, el uso de fibratos se ha asociado a una reducción marcada de los triglicéridos (20-50%) y a un incremento moderado del colesterol HDL (5-35%). El descenso del colesterol LDL es variable y puede llegar a ser del 5-20% (más con fenofibrato que con gemfibrozilo), pero en algunos casos, sobre todo en hipertrigliceridemias graves, pueden llegar a incrementar algo sus cifras. También incrementan el tamaño de las lipopartículas de LDL.\n\nLos ácidos grasos ω-3 (ácido eicosapentaenoico o EPA y ácido docosahexaenoico o DHA) son componentes del aceite de pescado y han sido utilizados en dosis altas en el tratamiento de la hipertrigliceridemia. El mecanismo de acción no es del todo conocido, pero en parte es por su habilidad para interaccionar con los PPAR y por reducir la secreción de apo B. Su efecto predominante es la disminución de los triglicéridos (20-45%). El efecto sobre otros parámetros lipídicos es de menor cuantía: incremento leve del colesterol HDL del 5% y escaso efecto sobre el colesterol LDL.\n\nReferencias:\n• Amor Fernández AJ, Vinagre Torres I, Perea Castilla V. Manual de Endocrinología y Nutrición [Internet]. Madrid: Sociedad Española de Endocrinología y Nutrición; 2018. Capítulo 125. Tratamiento de las dislipemias. [citado 11 de noviembre de 2019]. Disponible en: https://manual.seen.es/article?id=5559fe85-9644-42fd-966a-6a43ac18103c\n\n## 34. En relación con el tratamiento de la hiperlipidemia con estatinas, indique cuál de las siguientes afirmaciones es verdadera:\n\nA. Las estatinas pueden ser utilizadas sin riesgo durante el embarazo.\nB. En general, cuando se duplica la dosis de estatinas, se logra una reducción adicional de los niveles de colesterol de un 15%.\nC. Las estatinas son especialmente útiles en las hiperlipidemias con colesterol VLDL elevado.\nD. Fármacos metabolizados por el citocromo P450, como el ketoconazol, aumentan los niveles plasmáticos de estatinas y el riesgo de miopatía.\n\n### COMENTARIO\n\nLas estatinas son los fármacos más ampliamente utilizados para el tratamiento de los pacientes con dislipidemia y de los que hay una mayor evidencia de beneficios en la morbimortalidad cardiovascular. Su mecanismo de acción es la inhibición competitiva de la 3-hidroxi-3-metilglutaril-coenzima A (HMG-CoA) reductasa, bloqueando la conversión de la HMG-CoA en mevalonato, un paso precoz en la biosíntesis del colesterol a nivel hepático. Así, al disminuir la concentración intracelular de colesterol, incrementan el número de receptores de LDL a nivel del hepatocito, lo que aumenta la depuración del LDL plasmático y de otras partículas aterogénicas que contienen apo B. Se recomienda administrarlos por la noche, ya que es cuando la actividad de la HMG-CoA reductasa es más alta, y su eficacia hipocolesterolemiante es ampliamente reconocida, con unos efectos dosis-dependientes y diferentes, según el tipo de estatina usada, que pueden ser un descenso del colesterol LDL del 18-55%, un descenso de los triglicéridos de un 7-30% y un aumento del colesterol HDL del 5-15%.\n\nSe ha comprobado que doblar la dosis de cualquier estatina produce una reducción adicional del colesterol de un 6%, lo que se ha denominado \"la regla del 6\". Así, el incremento de una dosis inicial de atorvastatina de 10 mg a una dosis de 80 mg solo producirá una reducción adicional del colesterol del 18% (aumento de 10 a 20, de 20 a 40 y de 40 a 80 mg,\n---\n# OBESIDAD, LÍPIDOS Y TRASTORNOS ELECTROLÍTICOS 8\n\ncon un 6% de reducción del colesterol con cada incremento de la dosis). Obviamente, este fenómeno reduce la eficacia del incremento de la dosis de estatinas en la consecución de los objetivos terapéuticos necesarios en cada caso, y muy especialmente en los pacientes de alto riesgo.\n\nLas estatinas, en general, son muy bien toleradas, y el porcentaje de efectos secundarios descrito en los estudios es muy bajo. Los tres efectos secundarios característicos son: toxicidad muscular, toxicidad hepática e incremento del riesgo de DM2. La toxicidad muscular con estatinas va\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}